UKDTN expands portfolio of dementia clinical trials with leading industry partners 10 trials in 1 year The UK

Applications open for ARUK Doctoral Clinical Fellowship and UKDTN Clinical Trial Placement Pilot Clinicians interested in building a

UKDTN was proud to participate in the Alzheimer’s Association International Conference (AAIC) 2026, held in London. Bringing together

Promising Phase 2 findings presented at the Alzheimer’s Association International Conference (AAIC) 2026 have demonstrated that the investigational

A recent study, led by UKDTN’s Director – Professor Catherine Mummery – evaluated ImmunoBrain’s IBC-Ab002, a monoclonal antibody

The UK Dementia Trials Network (UKDTN) is pleased to announce its nomination for the Parliamentary Pathfinder – NHS

Building Momentum in Dementia Research: UKDTN Engages with the Scientific Community at the Alzheimer’s Research UK Research Conference

UKDTN launched its first Phase 1b Alzheimer’s trial, dosing the first patient in Europe and streamlining setup across sites, with further trials and collaborations in progress.  

On 3 December 2025, UKDTN convened the UK Industry Liaison Forum at CTAD 2025 in San Diego, bringing together global charities, international academic experts, and industry partners from over 20 pharma and biotech companies worldwide.

Over the past year, the UKDTN Coordinating Centre has grown exponentially, expanding to a dedicated team of 10 members to support the continued growth and delivery of the network.

At AAIC 2025, UKDTN hosted a roundtable on improving diversity in dementia trials, generating actionable insights now being developed into a white paper, with further international engagement planned at CTAD 2025.  

A joint UKDTN and Alzheimer’s Society survey of 1,200 patients and carers revealed strong interest in research but low participation, with findings to inform future UKDTN priorities and improve participant experience.